ISOLATED MAMMALIAN MONOCYTE CELL GENES; RELATED REAGENTS

1 . A composition of matter selected from the group consisting of:

a) a substantially pure or recombinant FDF03 protein or peptide exhibiting at least about 85% sequence identity over a length of at least about 12 amino acids to a mature polypeptide from SEQ ID NO:2 or 4;

b) a natural sequence FDF03 of SEQ ID NO:2 or 4;

c) a fusion protein comprising FDF03 sequence;

d) a substantially pure or recombinant YE01 protein or peptide exhibiting at least about 85% sequence identity over a length of at least about 12 amino acids to a mature polypeptide from SEQ ID NO:6, 8, or 10;

e) a natural sequence YE01 of SEQ ID NO:6, 8, or 10;

f) a fusion protein comprising YE01 sequence;

g) a substantially pure or recombinant KTE03 protein or peptide exhibiting at least about 85% sequence identity over a length of at least about 12 amino acids to SEQ ID NO:12, 14, 16, 18, 20, or 22;

h) a natural sequence KTE03 of SEQ ID NO:12, 14, 16, 18, 20, or 22; and

i) a fusion protein comprising KTE03 sequence.

2 . A substantially pure or isolated protein comprising a segment exhibiting sequence identity to a corresponding portion of a FDF03, YE01, or KTE03 of claim 1 , wherein:

a) said homology is at least about 90% identity and said portion is at least about 9 amino acids;

b) said homology is at least about 80% identity and said portion is at least about 17 amino acids; or

c) said homology is at least about 70% identity and said portion is at least about 25 amino acids.

3 . The composition of matter of claim 1 , wherein said:

a) FDF03 comprises a mature sequence of Table 1;

b) YE01 comprises a mature sequence of Table 2;

c) KTE03 comprises a mature sequence of Table 3;

d) protein or peptide: i) is from a warm blooded animal selected from a mammal, including a primate or rodent;

ii) comprises at least one polypeptide segment of SEQ ID NO:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, or 22;

iii) exhibits a plurality of portions exhibiting said identity;

iv) is a natural allelic variant of FDF03, YE01, or KTE03;

v) has a length at least about 30 amino acids;

vi) exhibits at least two non-overlapping epitopes which are specific for a mammalian FDF03, YE01, or KTE03;

vii) exhibits a sequence identity at least about 90% over a length of at least about 20 amino acids to a rodent FDF03, YE01, or KTE03;

viii) exhibits at least two non-overlapping epitopes which are specific for a primate FDF03, YE01, or KTE03;

ix) exhibits a sequence identity at least about 90% over a length of at least about 20 amino acids to a primate FDF03, YE01, or KTE03;

x) is glycosylated;

xi) has a molecular weight of at least 7 kD with natural glycosylation;

xii) is a synthetic polypeptide;

xiii) is attached to a solid substrate;

xiv) is conjugated to another chemical moiety;

xv) is a 5-fold or less substitution from natural sequence; or

xvi) is a deletion or insertion variant from a natural sequence.

4 . A composition comprising:

a) a sterile FDF03 protein or peptide of claim 1 ;

b) said FDF03 protein or peptide of claim 1 and a carrier, wherein said carrier is:

i) an aqueous compound, including water, saline, and/or buffer; and/or

ii) formulated for oral, rectal, nasal, topical, or parenteral administration;

c) a sterile YE01 protein or peptide of claim 1 ;

d) said YE01 protein or peptide of claim 1 and a carrier, wherein said carrier is:

i) an aqueous compound, including water, saline, and/or buffer; and/or

ii) formulated for oral, rectal, nasal, topical, or parenteral administration;

e) a sterile KTE03 protein or peptide of claim 1 ; or

f) said KTE03 protein or peptide of claim 1 and a carrier, wherein said carrier is:

i) an aqueous compound, including water, saline, and/or buffer; and/or

ii) formulated for oral, rectal, nasal, topical, or parenteral administration.

5 . The fusion protein of claim 1 , comprising:

a) mature protein sequence of Table 1, 2, or 3;

b) a detection or purification tag, including a FLAG, His6, or Ig sequence; or

c) sequence of another cell surface protein.

6 . A kit comprising a protein or polypeptide of claim 1 , and:

a) a compartment comprising said protein or polypeptide; and/or

b) instructions for use or disposal of reagents in said kit.

7 . A binding compound comprising an antigen binding portion from an antibody, which specifically binds to a natural FDF03, YE01, or KTE03 protein of claim 1 , wherein:

a) said protein is a rodent protein;

b) said binding compound is an Fv, Fab, or Fab2 fragment;

c) said binding compound is conjugated to another chemical moiety; or

d) said antibody:

i) is raised against a peptide sequence of a mature polypeptide of Table 1, 2, or 3;

ii) is raised against a mature FDF03, YE01, or KTE03;

iii) is raised to a purified FDF03, YE01, or KTE03;

iv) is immuno selected;

v) is a polyclonal antibody;

vi) binds to a denatured FDF03, YE01, or KTE03;

vii) exhibits a Kd to antigen of at least 30 μM;

viii) is attached to a solid substrate, including a bead or plastic membrane;

ix) is in a sterile composition; or

x) is detectably labeled, including a radioactive or fluorescent label.

8 . A kit comprising said binding compound of claim 7 , and:

a) a compartment comprising said binding compound; and/or

b) instructions for use or disposal of reagents in said kit.

9 . The kit of claim 8 capable of making a qualitative or quantitative analysis.

10 . A composition comprising:

a) a sterile binding compound of claim 7 ; or

b) said binding compound of claim 7 and a carrier, wherein said carrier is:

i) an aqueous compound, including water, saline, and/or buffer; and/or

ii) formulated for oral, rectal, nasal, topical, or parenteral administration.

11 . An isolated or recombinant nucleic acid encoding a protein or peptide or fusion protein of claim 1 , wherein:

a) said protein is from a Mammal, including a primate; or

b) said nucleic acid:

i) encodes an antigenic peptide sequence of Table 1, 2, or 3;

ii) encodes a plurality of antigenic peptide sequences of Table 1, 2, or 3;

iii) exhibits at least about 80% identity to a natural cDNA encoding said segment;

iv) is an expression vector;

v) further comprises an origin of replication;

vi) is from a natural source;

vii) comprises a detectable label;

viii) comprises synthetic nucleotide sequence;

ix) is less than 6 kb, preferably less than 3 kb;

x) is from a mammal, including a primate;

xi) comprises a natural full length coding sequence;

xii) is a hybridization probe for a gene encoding said protein; or

xiii) is a PCR primer, PCR product, or mutagenesis primer.

12 . A cell or tissue comprising a recombinant nucleic acid of claim 11 .

13 . The cell of claim 12 , wherein said cell is:

a) a prokaryotic cell;

b) a eukaryotic cell;

c) a bacterial cell;

d) a yeast cell;

e) an insect cell;

f) a mammalian cell;

g) a mouse cell;

h) a primate cell; or

i) a human cell.

14 . A kit comprising said nucleic acid of claim 11 , and:

a) a compartment comprising said nucleic acid;

b) a compartment further comprising a FDF03, YE01, or KTE03 protein or polypeptide; and/or

c) instructions for use or disposal of reagents in said kit.

15 . The kit of claim 14 capable of making a qualitative or quantitative analysis.

16 . A nucleic acid which:

a) hybridizes under wash conditions of 30° C. and less than 2M salt to the coding portion from SEQ ID NO:1 or 3;

b) hybridizes under wash conditions of 30° C. and less than 2 M salt to the coding portion from SEQ ID NO:5, 7, or 9;

c) hybridizes under wash conditions of 30° C. and less than 2M salt to the coding portion from SEQ ID NO:11, 13, 15, 17, 19, or 21;

d) exhibits at least about 85% identity over a stretch of at least about 30 nucleotides to a primate FDF03;

e) exhibits at least about 85% identity over a stretch of at least about 30 nucleotides to a primate YE01; or

f) exhibits at least about 85% identity over a stretch of at least about 30 nucleotides to a primate KTE03.

17 . The nucleic acid of claim 16 , wherein:

a) said wash conditions are at 45° C. and/or 500 mM salt; or

b) said identity is at least 90% and/or said stretch is at least 55 nucleotides.

18 . The nucleic acid of claim 17 , wherein:

a) said wash conditions are at 55° C. and/or 150 mM salt; or

b) said identity is at least 95% and/or said stretch is at least 75 nucleotides.

19 . A method of modulating physiology or development of a cell or tissue culture cell comprising contacting said cell with an agonist or antagonist of a FDF03, YE01, or KTE03.

20 . The method of claim 19 , wherein the cell is a leukocyte, and the antagonist is to YE01 and is a monoclonal antibody which binds to DLAIR-1.